John Sourbeer
Stock Analyst at UBS
(2.25)
# 1,558
Out of 4,412 analysts
33
Total ratings
57.14%
Success rate
-9.01%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMIC Singular Genomics Systems | Maintains: Neutral | $0.4 → $0.5 | $0.40 | +23.70% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $16.38 | +3.79% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $395.93 | +21.23% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $3.80 | +97.37% | 2 | Mar 5, 2024 | |
| QDEL QuidelOrtho | Downgrades: Sell | $70 → $42 | $39.64 | +5.95% | 1 | Mar 4, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $80.97 | +25.97% | 3 | Mar 1, 2024 | |
| WST West Pharmaceutical Services | Maintains: Neutral | $400 → $375 | $360.43 | +4.04% | 2 | Feb 16, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $13 → $12 | $1.47 | +716.33% | 2 | Feb 16, 2024 | |
| CTLT Catalent | Downgrades: Neutral | $58 → $64 | $55.92 | +13.56% | 4 | Feb 6, 2024 | |
| QGEN Qiagen | Maintains: Neutral | $49 → $43 | $41.65 | +3.87% | 3 | Nov 2, 2023 | |
| ILMN Illumina | Maintains: Neutral | $255 → $240 | $122.28 | +96.27% | 1 | Feb 14, 2023 | |
| TXG 10x Genomics | Initiates: Neutral | $50 | $27.59 | +81.23% | 1 | Feb 2, 2023 | |
| ICLR ICON PLC | Initiates: Buy | $270 | $308.31 | -12.43% | 1 | Sep 7, 2022 | |
| ABT Abbott Laboratories | Maintains: Buy | $142 → $128 | $107.53 | +19.04% | 2 | Jul 27, 2022 | |
| STVN Stevanato Group | Initiates: Neutral | n/a | $27.54 | - | 1 | Aug 10, 2021 |
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $0.4 → $0.5
Current: $0.40
Upside: +23.70%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $16.38
Upside: +3.79%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $395.93
Upside: +21.23%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $3.80
Upside: +97.37%
QuidelOrtho
Mar 4, 2024
Downgrades: Sell
Price Target: $70 → $42
Current: $39.64
Upside: +5.95%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $80.97
Upside: +25.97%
West Pharmaceutical Services
Feb 16, 2024
Maintains: Neutral
Price Target: $400 → $375
Current: $360.43
Upside: +4.04%
Pacific Biosciences of California
Feb 16, 2024
Maintains: Buy
Price Target: $13 → $12
Current: $1.47
Upside: +716.33%
Catalent
Feb 6, 2024
Downgrades: Neutral
Price Target: $58 → $64
Current: $55.92
Upside: +13.56%
Qiagen
Nov 2, 2023
Maintains: Neutral
Price Target: $49 → $43
Current: $41.65
Upside: +3.87%
Illumina
Feb 14, 2023
Maintains: Neutral
Price Target: $255 → $240
Current: $122.28
Upside: +96.27%
10x Genomics
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $27.59
Upside: +81.23%
ICON PLC
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $308.31
Upside: -12.43%
Abbott Laboratories
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $107.53
Upside: +19.04%
Stevanato Group
Aug 10, 2021
Initiates: Neutral
Price Target: n/a
Current: $27.54
Upside: -